Multiplexed drug testing of tumor slices using a microfluidic platform.

Area of Science:

• Oncology
• Biotechnology
• Microfluidics

Background:

• Current cancer drug response assessments are often inaccurate, slow, or expensive.
• Functional drug testing methods offer a promising alternative for personalized cancer therapy selection.
• Directly assessing patient tumor response to drugs can improve treatment outcomes.

Purpose of the Study:

• To develop and validate a microfluidic platform for multiplexed drug testing of intact human cancer slice cultures.
• To evaluate the platform's ability to rapidly assess drug responses in glioma xenografts and patient tumor biopsies.
• To establish a preclinical tool for improving cancer drug testing and personalized medicine.

Main Methods:

• Development of a digitally manufactured microfluidic device for culturing intact cancer slices.
• Multiplexed drug screening on slice cultures derived from human glioma xenografts and patient tumor biopsies.
• Evaluation of drug response by assessing tissue viability and drug efficacy within days of tissue acquisition.

Main Results:

• The microfluidic platform successfully enabled multiplexed drug testing on intact cancer slice cultures.
• Drug responses were evaluated in human glioma xenografts and patient tumor biopsies.
• The platform provided rapid results, within days of surgery, demonstrating its potential for guiding therapy selection.

Conclusions:

• The developed microfluidic platform is a viable preclinical tool for cancer drug testing and development.
• This approach preserves the tumor microenvironment, offering more accurate drug response assessments.
• The rapid turnaround time has the potential to significantly improve personalized cancer medicine by guiding initial therapy choices.